News | Intravascular Imaging | September 11, 2015

Infraredx Acquired by Nipro Corp.

Japanese medical company Nipro wants to expand into intravascular imaging solutions, expand vascular portfolio to the United States

Infraredx, NIRS, IVUS

September, 11, 2015 – Japanese medical vendor Nipro Corp. signed a definitive agreement to acquire Infraredx Inc., maker of a combined intravascular ultrasound (IVUS) integrated with near infrared spectroscopy (NIRS) for the detection of lipid-core plaque (LCP) coronary plaque. 

Nipro offers medical products and technologies in a wide range of fields, including artificial organs, circulatory devices, test/diagnostic agents, injection/infusion solutions, pharmaceuticals and medical glass products. The agreement combines Nipro's strong global cardiovascular portfolio and resources along with Infraredx’s industry expertise in NIRS and intravascular ultrasound. The agreement will help introduce Nipro’s cardiovascular product line into the United States. 

The company plans to continue Infraredx’s strategic plans to continue clinical testing of NIRS as an advanced imaging tool required to predict heart attacks and shift from reactive treatment to proactive care of coronary artery disease.

“By teaming up with one of the leading global medical equipment manufacturing companies in the world, Infraredx is able to leverage Nipro’s global network and vast resources to enhance its presence and impact a larger audience locally as well globally,” said Jason Bottiglieri, president and CEO of Infraredx. “We are pleased to combine our strengths to meet the demands of the marketplace and continue to deliver to the medical community cardiovascular imaging systems that hold the potential to revolutionize the management of cardiovascular disease.”

The acquisition, which is subject to certain conditions, is expected to close in October 2015.

For more information:

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init